136684-40-7Relevant articles and documents
Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives
Zhang, Hengyuan,Zhu, Peiqing,Liu, Jie,Yang, Xue,Xu, Shengtao,Yao, Hequan,Jiang, Jieyun,Ye, Wencai,Wu, Xiaoming,Xu, Jinyi
, p. 159 - 167 (2014)
A series of novel derivatives of 3-oxo-23-hydroxybetulinic acid was designed, synthesized, and evaluated for their antiproliferative activity against a panel of cancer cell lines (HL-60, BEL-7402, SF-763, HeLa, B16 and A375). The results indicated that majority of the derivatives exhibited more significant antitumor activity than the parent compound. In particular compound 10e showed the most potent activity with IC50values of 5.85, 6.23 and 7.22 μM against B16, SF-763 and BEL-7402 cells, respectively. Furthermore, 10e inhibited tumor growth by 51.8% and 62.7% (w/w) in H22 and B16 xenograft mouse models, comparable to cyclophosphamide and 5-fluorouracil, respectively.
Triterpenoids from Pulsatilla chinensis
Ye, Wen-Cai,Ji, Nine-Ning,Zhao, Shou-Xun,Liu, Jing-Han,Ye, Tao,McKervey,Stevenson
, p. 799 - 802 (1996)
A new lupane type triterpenic acid, pulsatillic acid, and two new lupane type triterpenoid glycosides, pulsatilloside A and B, along with the known 23-hydroxybetulinic acid were isolated from the roots of Pulsatilla chinensis. Their structures were characterized as 3-oxo-23-hydroxy-lup- 20(29)-en-28-oic acid, 3β, 23-dihydroxy-lup-20(29)-en-28-oic acid 3-O-α-L- arabinopyranoside and 3β, 23-dibydroxy-lup-20(29)-en-28-oic acid 28-O-β-D- glucopyranosyl-(1→6)-β-D-glucopyranoside on the basis of hydrolysis and spectral evidence including two-dimensional relay HOHAHA, one-dimensional multiple relay COSY and ROESY NMR techniques. Pulsatillic acid exhibited cytotoxic activities against P-388, Lewis lung carcinoma and human large- cell lung carcinoma.
NMDA AND MC RECEPTOR ANTAGONISTS EXHIBITING NEUROPROTECTIVE AND MEMORY ENHANCING ACTIVITIES
-
, (2009/01/20)
The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, methods of enhancing the brain's cognitive functions and methods of treating depression, anxiety and cachexia induced by a chronic disease in mammals and humans.
